Treatments in the study patients
| First-line treatment regimen | Number of patients (%) | After first-line therapy Number of patients (%) |
|---|---|---|
| Observation | 629 (80.4) | Observation only: 541 (69.2) |
| Some drug therapy: 88 (11.3) | ||
| One drug | 51 (6.5) | First-line drug continued*: 29 (3.7) |
| CAM | 43 (5.5) | Observation: 13 (1.7) |
| FQ | 3 (0.4) | Some other drug therapy: 9 (1.2) |
| EM | 1 (0.1) | |
| INH | 1 (0.1) | |
| Two drugs | 27 (3.5) | First-line drugs continued*: 10 (1.3) |
| CAM+FQ | 18 (2.3) | Observation: 10 (1.3) |
| CAM+EB | 2 (0.3) | Some other drug therapy: 7 (0.9) |
| CAM+RIF | 2 (0.3) | |
| EB+RIF | 2 (0.3) | |
| RIF+INH | 3 (0.4) | |
| Three drugs | 47 (6.0) | First-line drugs continued*: 16 (2.0) |
| RIF+INH+EB | 20 (2.6) | Observation: 21 (2.7) |
| CAM+RIF+EB | 19 (2.4) | Some other drug therapy: 10 (1.3) |
| CAM+INH+EB | 2 (0.3) | |
| CAM+RIF+FQ | 2 (0.3) | |
| Other combination | 4 (0.5) | |
| Four drugs | 28 (3.6) | First-line drugs continued*: 16 (2.0) |
| CAM+EB+RIF+SM | 12 (1.5) | Observation: 4 (0.5) |
| CAM+EB+RIF+FQ | 12 (1.5) | Some other drug therapy: 9 (1.2) |
| Other combination | 4 (0.5) |
*First-line drug(s) continued indicates that the first-line treatment regimen was continued throughout the follow-up period.
CAM, clarithromycin; EB, ethambutol: FQ, fluoroquinolone; INH, isoniazid; RIF, rifampin; SM, streptomycin.